HIV-1 Nef Assembles a Src Family Kinase-ZAP-70/Syk-PI3K Cascade to Downregulate Cell-Surface MHC-I

Cell Host and Microbe

Volumn 1, Issue 2, 2007, Pages 121-133

  Hung, Chien Hui ^a,d   Thomas, Laurel ^a   Ruby, Carl E ^b   Atkins, Katelyn M ^a   Morris, Nicholas P ^b   Knight, Zachary A ^c   Scholz, Isabel ^a   Barklis, Eric ^a   Weinberg, Andrew D ^b   Shokat, Kevan M ^c   Thomas, Gary ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

MICROBIO; MOLIMMUNO; SIGNALING

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE KINASE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL MEMBRANE; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, SMALL INTERFERING; ZAP-70 PROTEIN-TYROSINE KINASE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34147169409     PISSN: 19313128     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chom.2007.03.004     Document Type: Article

References (43)

1. Astoul E., Edmunds C., Cantrell D.A., and Ward S.G. PI 3-K and T-cell activation: Limitations of T-leukemic cell lines as signaling models. Trends Immunol. 22 (2001) 490-496
2. Bard F., Patel U., Levy J.B., Jurdic P., Horne W.C., and Baron R. Molecular complexes that contain both c-Cbl and c-Src associate with Golgi membranes. Eur. J. Cell Biol. 81 (2002) 26-35
3. Benedict C.A., Norris P.S., and Ware C.F. To kill or be killed: Viral evasion of apoptosis. Nat. Immunol. 3 (2002) 1013-1018
4. Blagoveshchenskaya A.D., Thomas L., Feliciangeli S.F., Hung C.H., and Thomas G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 111 (2002) 853-866
5. Carreno S., Gouze M.E., Schaak S., Emorine L.J., and Maridonneau-Parini I. Lack of palmitoylation redirects p59Hck from the plasma membrane to p61Hck-positive lysosomes. J. Biol. Chem. 275 (2000) 36223-36229
6. Chang A.H., O'Shaughnessy M.V., and Jirik F.R. Hck SH3 domain-dependent abrogation of Nef-induced class 1 MHC down-regulation. Eur. J. Immunol. 31 (2001) 2382-2387
7. Crump C.M., Hung C.H., Thomas L., Wan L., and Thomas G. Role of PACS-1 in trafficking of human cytomegalovirus glycoprotein B and virus production. J. Virol. 77 (2003) 11105-11113
8. Das S.R., and Jameel S. Biology of the HIV Nef protein. Indian J. Med. Res. 121 (2005) 315-332
9. Deane J.A., and Fruman D.A. Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu. Rev. Immunol. 22 (2004) 563-598
10. Druker B.J. Molecularly targeted therapy: Have the floodgates opened?. Oncologist 9 (2004) 357-360
11. Ely C.M., Tomiak W.M., Allen C.M., Thomas L., Thomas G., and Parsons S.J. pp60c-src enhances the acetylcholine receptor-dependent catecholamine release in vaccinia virus-infected bovine adrenal chromaffin cells. J. Neurochem. 62 (1994) 923-933
12. Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
13. Greene W.C. The brightening future of HIV therapeutics. Nat. Immunol. 5 (2004) 867-871
14. Hanna Z., Weng X., Kay D.G., Poudrier J., Lowell C., and Jolicoeur P. The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck. J. Virol. 75 (2001) 9378-9392
15. Husain M., Gusella G.L., Klotman M.E., Gelman I.H., Ross M.D., Schwartz E.J., Cara A., and Klotman P.E. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 13 (2002) 1806-1815
16. Kasper M.R., and Collins K.L. Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J. Virol. 77 (2003) 3041-3049
17. Keele B.F., Van Heuverswyn F., Li Y., Bailes E., Takehisa J., Santiago M.L., Bibollet-Ruche F., Chen Y., Wain L.V., Liegeois F., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313 (2006) 523-526
18. Keppler O.T., Tibroni N., Venzke S., Rauch S., and Fackler O.T. Modulation of specific surface receptors and activation sensitization in primary resting CD4+ T lymphocytes by the Nef protein of HIV-1. J. Leukoc. Biol. 79 (2006) 616-627
19. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125 (2006) 733-747
20. Larsen J.E., Massol R.H., Nieland T.J., and Kirchhausen T. HIV Nef-mediated major histocompatibility complex class I down-modulation is independent of Arf6 activity. Mol. Biol. Cell 15 (2004) 323-331
21. Le Gall S., Buseyne F., Trocha A., Walker B.D., Heard J.M., and Schwartz O. Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation. J. Virol. 74 (2000) 9256-9266
22. Lee C.H., Leung B., Lemmon M.A., Zheng J., Cowburn D., Kuriyan J., and Saksela K. A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J. 14 (1995) 5006-5015
23. Lerner E.C., and Smithgall T.E. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat. Struct. Biol. 9 (2002) 365-369
24. Linnemann T., Zheng Y.H., Mandic R., and Peterlin B.M. Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. Virology 294 (2002) 246-255
25. Luo W., and Peterlin B.M. Activation of the T-cell receptor signaling pathway by Nef from an aggressive strain of simian immunodeficiency virus. J. Virol. 71 (1997) 9531-9537
26. Moon K.D., Post C.B., Durden D.L., Zhou Q., De P., Harrison M.L., and Geahlen R.L. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J. Biol. Chem. 280 (2005) 1543-1551
27. Okkenhaug K., Bilancio A., Farjot G., Priddle H., Sancho S., Peskett E., Pearce W., Meek S.E., Salpekar A., Waterfield M.D., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 (2002) 1031-1034
28. Peterlin B.M., and Trono D. Hide, shield and strike back: How HIV-infected cells avoid immune eradication. Nat. Rev. Immunol. 3 (2003) 97-107
29. Piguet V., Wan L., Borel C., Mangasarian A., Demaurex N., Thomas G., and Trono D. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat. Cell Biol. 2 (2000) 163-167
30. Roeth J.F., Williams M., Kasper M.R., Filzen T.M., and Collins K.L. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J. Cell Biol. 167 (2004) 903-913
31. Scholz I., Arvidson B., Huseby D., and Barklis E. Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J. Virol. 79 (2005) 1470-1479
32. Scott G.K., Gu F., Crump C.M., Thomas L., Wan L., Xiang Y., and Thomas G. The phosphorylation state of an autoregulatory domain controls PACS-1-directed protein traffic. EMBO J. 22 (2003) 6234-6244
33. Scott G.K., Fei H., Thomas L., Medigeshi G.R., and Thomas G. A PACS-1, GGA3 and CK2 complex regulates CI-MPR trafficking. EMBO J 25 (2006) 4423-4435
34. Stevenson M. HIV-1 pathogenesis. Nat. Med. 9 (2003) 853-860
35. Stove V., Naessens E., Stove C., Swigut T., Plum J., and Verhasselt B. Signaling but not trafficking function of HIV-1 protein Nef is essential for Nef-induced defects in human intrathymic T-cell development. Blood 102 (2003) 2925-2932
36. Swann S.A., Williams M., Story C.M., Bobbitt K.R., Fleis R., and Collins K.L. HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology 282 (2001) 267-277
37. Swigut T., Alexander L., Morgan J., Lifson J., Mansfield K.G., Lang S., Johnson R.P., Skowronski J., and Desrosiers R. Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. J. Virol. 78 (2004) 13335-13344
38. Thoulouze M.I., Sol-Foulon N., Blanchet F., Dautry-Varsat A., Schwartz O., and Alcover A. Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse. Immunity 24 (2006) 547-561
39. Trible R.P., Emert-Sedlak L., and Smithgall T.E. HIV-1 Nef selectively activates SRC family kinases HCK, LYN, and c-SRC through direct SH3 domain interaction. J. Biol. Chem. 281 (2006) 27029-27038
40. Ward S., Sotsios Y., Dowden J., Bruce I., and Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 10 (2003) 207-213
41. Williams M., Roeth J.F., Kasper M.R., Filzen T.M., and Collins K.L. Human immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipitation of Nef with HLA-A2. J. Virol. 79 (2005) 632-636
42. Zauli G., Gibellini D., Secchiero P., Dutartre H., Olive D., Capitani S., and Collette Y. Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood 93 (1999) 1000-1010
43. Zhang Q., Cox D., Tseng C.C., Donaldson J.G., and Greenberg S. A requirement for ARF6 in Fcgamma receptor-mediated phagocytosis in macrophages. J. Biol. Chem. 273 (1998) 19977-19981